Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

Published:2016-12-23 Issue:1 Volume:3 Page:10-22
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Vandenberghe Rik¹²,Riviere Marie-Emmanuelle³,Caputo Angelika³,Sovago Judit⁴,Maguire R. Paul⁵,Farlow Martin⁶,Marotta Giovanni⁷,Sanchez-Valle Raquel⁸,Scheltens Philip⁹,Ryan J. Michael¹⁰,Graf Ana³

Affiliation:

1. Department of Neurosciences; KU Leuven; Leuven Belgium

2. Neurology Department; University Hospitals Leuven; Belgium

3. Neuroscience; Novartis Pharma AG; Basel Switzerland

4. Neuroscience Translational Medicine; Novartis Institutes for Biomedical Research; Basel Switzerland

5. Biomarker Development, Clinical Imaging; Novartis Institutes for Biomedical Research; Basel Switzerland

6. Department of Neurology; Indiana University School of Medicine; IN USA

7. Division of Geriatric Medicine; University of Toronto; Toronto Canada

8. Alzheimer's Disease and Other Cognitive Disorders Unit; Hospital Clinic; Barcelona Spain

9. Department of Neurology and Alzheimer Center; VU University Medical Center; Amsterdam The Netherlands

10. Novartis Pharmaceuticals Corporation; East Hanover NJ USA

Funder

Novartis Pharma

Novartis Pharma AG

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1016/j.trci.2016.12.003/fullpdf

Reference15 articles.

1. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial;Gilman;Neurology,2005

2. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization;Orgogozo;Neurology,2003

3. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid;Cribbs;Int Immunol,2003

4. A single ascending dose study of bapineuzumab in patients with Alzheimer disease;Black;Alzheimer Dis Assoc Disord,2010

5. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease;Siemers;Clin Neuropharmacol,2010

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer’s disease;Expert Opinion on Investigational Drugs;2024-08-26

2. Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review;ACS Chemical Neuroscience;2024-08-22

3. Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response;Vaccines;2024-06-14

4. Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects;Ibrain;2024-05-23

5. Immunotherapy: An emerging treatment option for neurodegenerative diseases;Drug Discovery Today;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3